Good Uptake of the COVID-19 Vaccine among Patients with Rheumatic
Diseases in the United Arab Emirates (UAE)

Azza   A.M.   Elsheikh; Humeira      Badsha

doi:10.2174/03666211230090639

Abstract

Background: Many patients with rheumatic diseases are immunosuppressed and take forms of immunomodulator medication. Hence, these patients might be at a heightened risk of Covid-19 and have special concerns in regard to vaccines, such as safety and efficacy. Vaccines have been available for the population of UAE as of January 2021, these being Pfizer (the United States and Europe), Sinopharm (China), and AstraZeneca (United Kingdom). The aim of our paper was to examine the rate of vaccine uptake among our patients with rheumatic conditions in the United Arab Emirates.

Methods: A questionnaire was distributed among patients with rheumatic diseases attending a rheumatology specialised clinic in the United Arab Emirates. We collected data on 149 consecutive patients who were seen during a one-month period from 10/06/2021 to 10/07/2021 in Dubai.

Results: The mean age of the patients was 45.9 +/- 41.3. The majority of the patients had underlying rheumatic diseases (86.9%), the rest having conditions such as soft tissue pain or to rule out rheumatic conditions. 48.5% were taking immunomodulators. 41.7% of respondents had other chronic diseases. It was also found that 18.9% had Covid-19 previously, all of whom recovered, with the average duration of the illness being 11 days. 99.1% of individuals reported that receiving the Covid-19 vaccine was extremely important, and 95.0% had already received the vaccination. Their reasoning for receiving the vaccination varied from medical advice (17.5%), general worry about infection/ reinfection of Covid-19 (65.3%), in order to travel (8.4%), employee requirement (5.6%), and other reasons (3.2%). Specifically, 48.3% chose the Pfizer vaccine, 39.8% had Sinopharm, and 11.9% had AstraZeneca. These decisions on which vaccine to choose were influenced by the availability of the vaccine (35.1%), medical advice (16.9%), effectiveness (15.5%), safety and side effect profile (18.2%), age restrictions (2.7%), experience/ advice from friends and family (8.1%) and other reasons (3.4%).

Conclusion: Overall, an overwhelming majority of our patients (95.0%) with rheumatic diseases in the specialised muscular-skeletal clinic in the UAE have received the Covid-19 vaccine. This reflects good public health service messaging and concentrated efforts from the medical community, UAE government, and the patient’s rheumatologists.

Keywords: COVID-19, Vaccination, Hesitancy, Rheumatic disease, World Health Organization, AstraZeneca.

[1] 
Centers for Disease Control and Prevention. 2021. COVID-19 and Your Health.  Available at:
                    https://www.cdc.gov/
                        coronavirus/2019-ncov/need-extraprecautions/people-with-medical-conditions.html
[2] 
Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis  2021; 80(7): 930-42.
[http://dx.doi.org/10.1136/annrheumdis-2020-219498] [PMID: 33504483] 
[3] 
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature  2020; 584(7821): 430-6.
[http://dx.doi.org/10.1038/s41586-020-2521-4] [PMID: 32640463] 
[4] 
Arthritis.org. 2021. Available at:
                    https://www.arthritis.org/health
                        wellness/about-arthritis/related-conditions/other-diseases/acr-COVID-19-vaccineclinical-guidance
[5] 
Landau M, Alexa Meara M. Rheumatoid arthritis and COVID-19 vaccination: Questions and answers | everyday health. EverydayHealthcom 2021. Available at:
                    https://www.everyday
                        health.com/rheumatoidarthritis/things-people-with-rheumatoid-arthritis-must-know-about-the-COVID-19vaccines/
[6] 
Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021.
[http://dx.doi.org/10.1136/annrheumdis-2021-220597] 
[7] 
Cerda AA, García LY. Hesitation and refusal factors in individuals’ decision-making processes regarding a coronavirus disease 2019 vaccination. Front Public Health  2021; 9: 626852.
[http://dx.doi.org/10.3389/fpubh.2021.626852] [PMID: 33968880] 
[8] 
Eguia H, Vinciarelli F, Bosque-Prous M, Kristensen T, Saigí-Rubió F. Spain’s hesitation at the gates of a COVID-19 vaccine. Vaccines (Basel)  2021; 9(2): 170.
[http://dx.doi.org/10.3390/vaccines9020170] [PMID: 33670621] 
[9] 
İkiışık H, Akif Sezerol M, Taşçı Y, Maral I. COVID-19 vaccine hesitancy: A community-based research in Turkey. Int J Clin Pract  2021; 75(8): e14336.
[http://dx.doi.org/10.1111/ijcp.14336] [PMID: 33973322] 
[10] 
Nytimes.com. Vaccine skepticism was viewed as a knowledge problem. It’s actually about gut beliefs. 2021. Available at:
                    https://www.nytimes.com/2021/04/29/us/vaccine-skepticism-beliefs.html
[11] 
Amin AB, Bednarczyk RA, Ray CE, et al. Association of moral values with vaccine hesitancy. Nat Hum Behav  2017; 1(12): 873-80.
[http://dx.doi.org/10.1038/s41562-017-0256-5] [PMID: 31024188] 
[12] 
Staff R. Global vaccine trust rising, but France, Japan, others sceptical. U.S. 2021. Available at:
                    https://www.reuters.com
                        /article/us-health-coronavirus-vaccinesconfidenc-idUSKBN2A400T
[13] 
Hannah Recht L. Black americans are getting vaccinated at lower rates than white americans. kaiser health news. 2021. Available at:
                    https://khn.org/news/article/black-americans-are-getting-vaccinated-at-lower-ratesthan-white-americans/
[14] 
Hamel L, Artiga S, Safarpour A, Stokes M, Brodie M. KFF COVID-19 vaccine monitor: COVID-19 vaccine access, information, and experiences among hispanic adults in the U.S. KFF. 2021. Available at:
                    https://www.kff.org/
                        coronavirus-COVID-19/poll-finding/ff-COVID-19-vaccinemonitor-access-information-experiences-hispanic-adults/